You left it unfinished. Here's the whole thing:

Quote:

---

MILFORD, Pa., March 11, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (MNZO), today announced Manzo Pharmaceuticals has identified Medicus Research to perform the human clinical study of Lacto-Freedom probiotic, a necessary step in order to take the ground breaking product to market.

The goal of this human study is to use science to substantiate that the Lacto-Freedom™ Probiotic demonstrates efficacy in decreasing symptoms of Lactose Intolerance when consuming a glass of milk. Dr. Jay Udani, CEO of Medicus Reseach, concurred that the FDA recognizes genetically modified probiotics, like Lacto-Freedom probiotic, as nutritional supplements and there are no additional regulations that pertain to genetically modified probiotics. Dr. Jay Udeni has expertise in FDA regulations, probiotics development and deployment, clinical studies, as well as Federal Trade Commission regulation compliance. Medicus Research designs its clinical trials to guarantee that its studies are structurally and functionally compliant, and follow the strict guidelines that are in place. Medicus has established Good Clinical Practice and FDA compliant procedures, internal quality assurance processes, and proprietary management technology systems, which ensure the highest quality for all aspects of the study. Consumers can find out more about Medicus at : www.medicusresearch.com/

Prior to this clinical trial Manzo Pharmaceuticals and Celprogen will run a small pilot study with a limited number of human subjects to make sure the dose is adequate and that no modifications in the study need to be made before commencing the formal in depth human clinical study. Once a successful human study is completed, Lacto-Freedom probiotic can go to market, and the company feels confident that it will change the lives of those suffering from lactose intolerance. Manzo Pharmaceuticals anticipates a successful human study and is already in talks with several manufacturers of probiotics to be ready to go straight to market.

http://finance.yahoo.com/news/manzo-pharmaceu...00761.html

---